LAVA Free Cash Flow Per Share from 2010 to 2024

LVTX Stock  USD 1.60  0.05  3.23%   
LAVA Therapeutics Free Cash Flow Per Share yearly trend continues to be fairly stable with very little volatility. Free Cash Flow Per Share will likely drop to -1.56 in 2024. Free Cash Flow Per Share is the amount of cash LAVA Therapeutics NV generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. View All Fundamentals
 
Free Cash Flow Per Share  
First Reported
2010-12-31
Previous Quarter
(1.49)
Current Value
(1.56)
Quarterly Volatility
0.47758595
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LAVA Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LAVA Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 158.4 K, Net Interest Income of 3.1 M or Depreciation And Amortization of 1.3 M, as well as many indicators such as Price To Sales Ratio of 5.93, Dividend Yield of 0.0 or PTB Ratio of 0.78. LAVA financial statements analysis is a perfect complement when working with LAVA Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LAVA Therapeutics Correlation against competitors.

Latest LAVA Therapeutics' Free Cash Flow Per Share Growth Pattern

Below is the plot of the Free Cash Flow Per Share of LAVA Therapeutics NV over the last few years. It is the amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share. LAVA Therapeutics' Free Cash Flow Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LAVA Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Per Share10 Years Trend
Slightly volatile
   Free Cash Flow Per Share   
       Timeline  

LAVA Free Cash Flow Per Share Regression Statistics

Arithmetic Mean(0.73)
Geometric Mean0.64
Coefficient Of Variation(65.68)
Mean Deviation0.34
Median(0.58)
Standard Deviation0.48
Sample Variance0.23
Range1.8209
R-Value(0.44)
Mean Square Error0.20
R-Squared0.19
Significance0.10
Slope(0.05)
Total Sum of Squares3.19

LAVA Free Cash Flow Per Share History

2024 -1.56
2023 -1.49
2022 0.13
2021 -1.69
2020 -0.53

About LAVA Therapeutics Financial Statements

LAVA Therapeutics investors use historical fundamental indicators, such as LAVA Therapeutics' Free Cash Flow Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LAVA Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Free Cash Flow Per Share(1.49)(1.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.